2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Matthew J. Matasar, MD, attending physician, Memorial Sloan Kettering Cancer Center, discusses antibody drug conjugates in B-cell malignancies.
Matthew J. Matasar, MD, attending physician, Memorial Sloan Kettering Cancer Center, discusses antibody drug conjugates (ADCs) in B-cell malignancies.
Polatuzumab vedotin, an ADC, is being studied in combination with rituximab (Rituxan) or obinutuzumab (Gazyva) in patients with relapsed/refractory follicular lymphoma or diffuse large B-cell lymphoma (DLBCL).
As for ADCs in this space, there has been success with brentuximab vedotin, which is approved by the FDA in classical Hodgkin lymphoma.